CED Digest: 50 Items — April 02, 2026

Alabama Medical Cannabis Sales Gear for Spring 2026 Launch

Alabama’s medical cannabis sales are scheduled to launch in spring 2026, establishing a regulated market that clinicians will need to understand for patient recommendations and program participation.

Cannabis compounds CBD and CBG may help reverse fatty liver disease, study finds

Cannabis compounds CBD and CBG show potential to reverse fatty liver disease, offering clinicians a possible therapeutic application for a common liver condition affecting millions worldwide.

From Billion-Dollar Hemp Drinks to FDA Cease-and-Desist Letters: The Cannabis Industry’s …

The article examines regulatory conflicts between growing hemp-derived cannabis product sales and FDA enforcement actions, which directly impacts clinical practice and patient access to cannabinoid therapies.

Cannabis Compounds CBD and CBG Show Promise in Reducing Liver Fat and Improving …

Preclinical research demonstrates CBD and CBG reduce hepatic lipid accumulation, offering potential therapeutic applications for cannabis clinicians treating patients with fatty liver disease.

New Cannabis Group Will Help Ground Policy In Science And Patient Experience As …

New Top Cannabis Regulator Sets Priorities In First Board Meeting

A newly appointed cannabis regulator outlined priorities at their initial board meeting, establishing regulatory direction that affects clinical practice standards and compliance requirements for healthcare providers.

Brazil’s Cannabis Crossroads: New Rules, Old Truths, and the Road Ahead

Brazil implements new cannabis regulations while addressing established medical applications, directly impacting clinical prescribing practices and patient access for licensed healthcare providers.

2 Greater Cincinnati breweries file lawsuit over Ohio ban on THC beverages – WLWT

Two Greater Cincinnati breweries are challenging Ohio’s prohibition on THC-infused beverages through legal action, raising questions about cannabis product regulation and market access in the state.

New Ohio law means THC-infused drinks won’t be available on many store shelves – WTVG

Ohio’s new law restricts THC-infused beverage distribution in retail settings, affecting product availability and potentially impacting patient access to alternative cannabis delivery methods.

Lawmakers strike down bill capping THC levels in Oregon’s cannabis edibles – Yahoo

Oregon legislators rejected a bill that would have limited THC content in cannabis edibles, affecting dosing standardization and patient safety considerations in clinical practice.

Attempt to limit potency of THC in marijuana edibles fails at Oregon Legislature

Oregon legislators failed to pass regulations limiting THC potency in marijuana edibles, affecting clinical dosing standardization and patient safety management for practitioners.

Cannabis Compounds CBD and CBG Slash Liver Fat and Restore Metabolic Health

**Clinician Summary:** CBD and CBG cannabinoids demonstrated effects on hepatic steatosis and metabolic parameters, providing evidence relevant to cannabis use in metabolic disease management.

Cannabinoid Oral Mucosal Delivery: Approaches to Formulation, Fabrication, and … – PubMed

This article examines formulation and fabrication methods for delivering cannabinoids through oral mucosal routes, relevant to clinicians seeking alternative administration pathways with potentially improved bioavailability and patient compliance.

Study: CBD-Dominant Cannabis Products Provide Significant Anxiety Relief – NORML

CBD-dominant cannabis products demonstrate efficacy for anxiety treatment, providing clinicians with evidence-based data for patient dosing and product recommendations.

Clinical Trial: Cannabis Extracts Significantly Reduce Myofascial Pain – NORML

A clinical trial demonstrates cannabis extracts’ efficacy in reducing myofascial pain, providing clinicians with evidence-based data for treating this common musculoskeletal condition.

As a Medical Cannabis Patient, I’m Watching This Supreme Court Case Closely

This article covers a Supreme Court case relevant to medical cannabis patients and discusses its clinical implications for cannabis medicine practice. —

The Week in Weed: March 2026 | Seyfarth Shaw LLP – JDSupra

This article covers cannabis legal developments and regulatory updates from March 2026, providing clinicians with current information on evolving laws that may affect prescribing practices and patient care recommendations.

Marijuana gummies sold in Ohio recalled. Why, where they were sold – The Columbus Dispatch

Marijuana gummies sold in Ohio were recalled, requiring clinicians to counsel patients about potential product safety issues and verify medication sourcing.

New Group Launches Ahead of Medicare CBD Pilots – Cannabis Wire

A new group has formed to prepare for upcoming Medicare CBD pilot programs, which could expand insurance coverage and clinical research opportunities for cannabis-based treatments.

Marijuana Status Based Prohibition Tag Archives – Powers Law Firm PA

This archive covers legal prohibitions and regulatory statuses of marijuana across jurisdictions, relevant to clinicians navigating cannabis prescription legality and patient counseling requirements.

Louisiana lawmaker files bill to legalize recreational marijuana through licensed dispensaries

A Louisiana legislator proposed legalization of recreational marijuana via licensed dispensaries, which affects clinicians’ prescribing practices, patient counseling, and regulatory compliance in cannabis medicine.

Mom’s homemade medical cannabis recipe now being sold at Georgia dispensaries

A Georgia mother’s homemade medical cannabis formulation has been commercialized and is now available through licensed dispensaries, representing patient-derived product innovation in a regulated state market.

Ohio THC drink ban draws lawsuit from Cincinnati breweries

Ohio’s THC beverage restrictions prompt legal challenge from breweries, creating regulatory uncertainty that clinicians must monitor for evolving cannabis product availability and patient access implications.

Israeli researchers find cannabis compounds could lead to 1st drug for fatty liver disease

Israeli researchers identified cannabis compounds as potential therapeutic agents for fatty liver disease, a condition affecting millions globally with limited treatment options.

Virginia adult-use sales bills pass both chambers, head to conference committee! – Blog

Virginia’s adult-use cannabis sales legislation passed both legislative chambers and requires reconciliation, potentially affecting patient access, medical program interactions, and clinical practice environments.

Study highlights pros, cons of medical marijuana as its future in Tennessee remains unknown

A Tennessee study examines medical marijuana’s therapeutic benefits and risks, relevant to clinicians as the state’s regulatory status for clinical cannabis use remains undetermined.

2026 Utah legislature on cannabis, psychedelics and kratom – Fox 13

The article covers Utah’s 2026 legislative session actions on cannabis, psychedelics, and kratom—directly impacting clinicians’ ability to prescribe, recommend, or reference these substances in clinical practice.

Oregon Bill To Ban Marijuana Edibles With More Than 10 Milligrams Of THC Fails

Oregon legislators rejected a proposal to limit THC content in cannabis edibles to 10mg per unit, affecting dosing standards and patient access to higher-potency products.

Georgia bill could limit probable cause for smell of marijuana, cannabis, or hemp – YouTube

Georgia legislation would restrict police authority to use marijuana/hemp odor alone as probable cause for searches, potentially affecting legal compliance documentation and patient privacy protections.

Study reveals cannabis compounds reduce threat of fatty liver disease | Health

Cannabinoid compounds demonstrate therapeutic potential for reducing fatty liver disease progression, providing clinicians with evidence-based rationale for patient counseling on specific cannabis-related health outcomes.

Prescription Cannabidiol CBD Oil Market to Hit US$ 190.9 Billion by 2032 at 23.48% CAGR

This market analysis projects prescription CBD oil will reach $190.9 billion by 2032, indicating significant growth potential that clinicians should monitor for evolving pharmaceutical CBD products and clinical applications.

TPS Cannabis News – StratCann

InMed Pharmaceuticals Shifts Focus to Therapeutic Programs, Ends BayMedica’s Non …

InMed Pharmaceuticals is reallocating resources from BayMedica’s non-cannabinoid work toward therapeutic cannabis programs, signaling industry consolidation and shifting investment priorities in cannabinoid drug development.

Cannabis Extracts Significantly Reduce Myofascial Pain | Trending – Labroots

The article reports research findings on cannabis extracts’ efficacy in treating myofascial pain, relevant for clinicians evaluating cannabis as a therapeutic option for musculoskeletal pain management.

Pediatricians warn about cannabis use disorder, kids’ easy access to the drug – YouTube

Pediatricians highlight cannabis use disorder in children and accessibility concerns, directly informing clinicians about developmental risk factors and prevention/treatment considerations for younger populations.

West Virginia House Passes Bill To Allocate Medical Marijuana Revenue, With Some …

West Virginia legislation allocates medical marijuana tax revenue, requiring clinicians to understand funding mechanisms that may affect patient access and program implementation.

Study highlights positive, negatives of medical marijuana – WKRN News 2

This article discusses research findings on medical marijuana’s therapeutic benefits and adverse effects, relevant for clinicians evaluating clinical evidence and patient risk-benefit profiles.

The science behind roadside THC testing and diving into SGI’s zero-tolerance policy – Global News

This article examines roadside THC detection methods and Saskatchewan Government Insurance’s zero-tolerance cannabis policy, relevant to clinicians assessing impairment and patient driving safety counseling.

Mom’s homemade medical cannabis recipe now being sold at Georgia dispensaries

A Georgia mother’s homemade medical cannabis formulation has entered commercial dispensary distribution, demonstrating patient-developed products gaining regulatory approval and market access in licensed states.

‘Pot for Potholes Act’ aims to legalize marijuana in Tennessee and distribute taxes to repair …

Tennessee legislation proposes legalizing marijuana while dedicating tax revenue to infrastructure repair, creating potential clinical access pathways and funding implications for cannabis medicine practitioners.

One of Colorado’s Largest Dispensary Chains Agrees to Buyout – Denver Westword

A major Colorado dispensary chain is being acquired, potentially affecting patient access, pricing, and product availability across multiple retail locations serving the state’s cannabis patient population.

Cannabis legalization driving increases in marijuana use among US adults with historically … – MSN

Cannabis legalization correlates with increased marijuana use among historically marginalized US adult populations, informing clinicians about demographic shifts in patient populations and screening priorities.

Ohio Department of Commerce recalls certain marijuana gummies lacking THC symbol … – Facebook

Ohio’s Department of Commerce recalled marijuana gummies missing required THC labeling symbols, highlighting regulatory compliance importance for product safety and legal distribution in medical cannabis dispensaries.

Perceptions of the relative harmfulness of marijuana and alcohol among adults in Oregon.

This study examines how Oregon adults perceive the health risks of marijuana versus alcohol, providing clinicians with data on patient beliefs that may influence treatment discussions and compliance.

What’s Really Happening With Cannabis ETF MSOS? – The Dales Report

MSOS is a cannabis ETF; understanding its performance and composition matters to clinicians tracking industry consolidation and company stability affecting patient access and product availability.

Study reveals cannabis compounds reduce threat of fatty liver disease – Daily Journal

Cannabis compounds show potential to reduce fatty liver disease risk, offering clinicians evidence-based information for patient counseling and treatment considerations.

Scientists are raising new concerns about marijuana use in teens – KPBS

This article addresses research linking adolescent cannabis use to psychiatric risks, which is critical for clinicians evaluating cannabis safety profiles in teen patients.

Clinical Trial: Cannabis Extracts Significantly Reduce Myofascial Pain – NORML

Cannabis extracts reduced myofascial pain in temporomandibular disorder patients, offering clinicians evidence for cannabinoid treatment in conditions resistant to conventional pharmacotherapy.

Can the placenta predict schizophrenia risk? Lessons from prenatal cannabis exposure

Prenatal THC exposure may disrupt fetal neurodevelopment via endocannabinoid system disruption, with placental biomarkers potentially identifying early schizophrenia risk in offspring.

Scientists are raising new concerns about marijuana use in teens – YouTube

This article examines THC’s effects on the developing adolescent brain and links early frequent cannabis use to disruptions, which clinicians must consider when treating younger patients.

The digest reflects an emerging clinical interest in specific cannabinoid profiles, particularly CBD and CBG, for metabolic and pain-related conditions, alongside growing evidence from controlled studies on anxiety and myofascial pain management. Concurrently, regulatory frameworks across multiple jurisdictions are evolving in divergent directions, with some states implementing potency restrictions while others liberalize access through beverage formulations, creating fragmented clinical guidance for practitioners. These parallel developments underscore the tension between preliminary therapeutic promise and the practical challenges of standardized dosing, quality control, and evidence-based clinical integration that currently limit cannabinoid therapeutics in mainstream medical practice.

FAQ

This News item was assembled from structured source metadata and pipeline scoring.